These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35177083)

  • 1. Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways.
    Szilágyi SS; Amsalem-Zafran AR; Shapira KE; Ehrlich M; Henis YI
    BMC Biol; 2022 Feb; 20(1):50. PubMed ID: 35177083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.
    Olsen OE; Hella H; Elsaadi S; Jacobi C; Martinez-Hackert E; Holien T
    Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32235336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
    Olsen OE; Wader KF; Hella H; Mylin AK; Turesson I; Nesthus I; Waage A; Sundan A; Holien T
    Cell Commun Signal; 2015 Jun; 13():27. PubMed ID: 26047946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
    Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
    J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic proteins.
    Chen D; Zhao M; Mundy GR
    Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.
    Macías-Silva M; Hoodless PA; Tang SJ; Buchwald M; Wrana JL
    J Biol Chem; 1998 Oct; 273(40):25628-36. PubMed ID: 9748228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A.
    Szilágyi SS; Burdzinski W; Jatzlau J; Ehrlich M; Knaus P; Henis YI
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
    Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engagement of activin and bone morphogenetic protein signaling pathway Smad proteins in the induction of inhibin B production in ovarian granulosa cells.
    Bondestam J; Kaivo-oja N; Kallio J; Groome N; Hydén-Granskog C; Fujii M; Moustakas A; Jalanko A; ten Dijke P; Ritvos O
    Mol Cell Endocrinol; 2002 Sep; 195(1-2):79-88. PubMed ID: 12354674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.
    Korupolu RV; Muenster U; Read JD; Vale W; Fischer WH
    J Biol Chem; 2008 Feb; 283(7):3782-90. PubMed ID: 18056265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin.
    Glister C; Kemp CF; Knight PG
    Reproduction; 2004 Feb; 127(2):239-54. PubMed ID: 15056790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular interpretation of multiple TGF-beta signals: intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads.
    Candia AF; Watabe T; Hawley SH; Onichtchouk D; Zhang Y; Derynck R; Niehrs C; Cho KW
    Development; 1997 Nov; 124(22):4467-80. PubMed ID: 9409665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein 2 stimulates noncanonical SMAD2/3 signaling via the BMP type 1A receptor in gonadotrope-like cells: implications for FSH synthesis.
    Wang Y; Ho CC; Bang E; Rejon CA; Libasci V; Pertchenko P; Hébert TE; Bernard DJ
    Endocrinology; 2014 May; 155(5):1970-81. PubMed ID: 24601881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.
    Rejon CA; Hancock MA; Li YN; Thompson TB; Hébert TE; Bernard DJ
    Cell Signal; 2013 Dec; 25(12):2717-26. PubMed ID: 24018044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
    Tsuchida K; Nakatani M; Uezumi A; Murakami T; Cui X
    Endocr J; 2008 Mar; 55(1):11-21. PubMed ID: 17878607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
    Upton PD; Davies RJ; Trembath RC; Morrell NW
    J Biol Chem; 2009 Jun; 284(23):15794-804. PubMed ID: 19366699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory roles of bone morphogenetic proteins and glucocorticoids in catecholamine production by rat pheochromocytoma cells.
    Kano Y; Otsuka F; Takeda M; Suzuki J; Inagaki K; Miyoshi T; Miyamoto M; Otani H; Ogura T; Makino H
    Endocrinology; 2005 Dec; 146(12):5332-40. PubMed ID: 16150914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.
    Aykul S; Martinez-Hackert E
    J Biol Chem; 2016 May; 291(20):10792-804. PubMed ID: 26961869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of stable homomeric and transient heteromeric bone morphogenetic protein (BMP) receptor complexes regulates Smad protein signaling.
    Marom B; Heining E; Knaus P; Henis YI
    J Biol Chem; 2011 Jun; 286(22):19287-96. PubMed ID: 21471205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
    Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
    Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.